Tango Therapeutics/$TNGX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Tango Therapeutics
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
Ticker
$TNGX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
155
ISIN
US87583X1090
Website
TNGX Metrics
BasicAdvanced
$533M
-
-$1.21
1.03
-
Price and volume
Market cap
$533M
Beta
1.03
52-week high
$12.02
52-week low
$1.03
Average daily volume
4.5M
Financial strength
Current ratio
6.262
Quick ratio
6.034
Long term debt to equity
20.462
Total debt to equity
22.156
Profitability
EBITDA (TTM)
-143.374
Gross margin (TTM)
-247.15%
Net profit margin (TTM)
-322.67%
Operating margin (TTM)
-355.87%
Effective tax rate (TTM)
-0.15%
Revenue per employee (TTM)
$260,000
Management effectiveness
Return on assets (TTM)
-26.79%
Return on equity (TTM)
-61.35%
Valuation
Price to revenue (TTM)
13.174
Price to book
3.19
Price to tangible book (TTM)
3.19
Price to free cash flow (TTM)
-3.972
Free cash flow yield (TTM)
-25.18%
Free cash flow per share (TTM)
-123.86%
Growth
Revenue change (TTM)
10.09%
Earnings per share change (TTM)
7.46%
3-year revenue growth (CAGR)
4.02%
3-year earnings per share growth (CAGR)
7.54%
What the Analysts think about TNGX
Analyst ratings (Buy, Hold, Sell) for Tango Therapeutics stock.
Bulls say / Bears say
Tango Therapeutics has recently announced a strategic partnership with a major pharmaceutical company to co-develop novel cancer therapies, potentially accelerating its pipeline and revenue growth. (bloomberg.com)
The company's lead candidate, TNG908, has shown promising results in early-phase clinical trials for treating glioblastoma, a market with significant unmet needs. (reuters.com)
Tango Therapeutics reported a 25% increase in year-over-year revenue in its latest quarterly earnings, indicating strong financial health and operational efficiency. (seekingalpha.com)
The company faces potential delays in its clinical trials due to regulatory challenges, which could postpone product launches and revenue realization. (bloomberg.com)
Tango Therapeutics' recent financial statements reveal a significant increase in R&D expenses, leading to a net loss that may concern investors about its profitability trajectory. (reuters.com)
A key competitor has recently received FDA approval for a similar cancer therapy, potentially diminishing Tango's market share upon its product's release. (seekingalpha.com)
Data summarised monthly by Lightyear AI. Last updated on 10 Jun 2025.
TNGX Financial Performance
Revenues and expenses
TNGX Earnings Performance
Company profitability
TNGX News
AllArticlesVideos
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer
GlobeNewsWire·5 hours ago
Tango Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
GlobeNewsWire·1 month ago
Tango Therapeutics Announces First Patient Dosed in TNG456 Phase 1/2 Trial in Patients With MTAP-deleted Glioblastomas and Other Solid Tumors
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Tango Therapeutics stock?
Tango Therapeutics (TNGX) has a market cap of $533M as of June 27, 2025.
What is the P/E ratio for Tango Therapeutics stock?
The price to earnings (P/E) ratio for Tango Therapeutics (TNGX) stock is 0 as of June 27, 2025.
Does Tango Therapeutics stock pay dividends?
No, Tango Therapeutics (TNGX) stock does not pay dividends to its shareholders as of June 27, 2025.
When is the next Tango Therapeutics dividend payment date?
Tango Therapeutics (TNGX) stock does not pay dividends to its shareholders.
What is the beta indicator for Tango Therapeutics?
Tango Therapeutics (TNGX) has a beta rating of 1.03. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.